ProtFus

ProtFus identifies and characterizes protein-protein interactions associated with fusion proteins in cancer by mining scientific literature and integrating validated interaction data.


Key Features:

  • Text Mining Approach: Employs text mining of scientific literature to extract evidence of protein-protein interactions (PPIs) related to fusion proteins.
  • Chimeric Protein-Protein Interactions (ChiPPI): Incorporates the ChiPPI method to predict and characterize chimeric PPIs and their effects on cellular networks.
  • Validation and Prediction: Uses an online literature search for validation and a Naïve Bayes classifier trained on a set of 358 fusion proteins with corresponding PPIs to identify reliable evidence.
  • Comprehensive Screening: Demonstrated capability to screen large datasets, identifying 2,908 PPIs across 18 cancer types from a test set of 1,817 fusion proteins.

Scientific Applications:

  • Network Alteration Analysis: Enables study of how fusion proteins alter protein interaction networks in various cancers.
  • Genomic–Phenotype Correlation: Supports investigation of relationships among genomic features, disease pathology, and drug metabolism in cancer patients.
  • Therapeutic Insight: Provides validated molecular interaction data to inform tailored therapy approaches based on fusion-protein-specific interactions.
  • Mechanism Exploration: Aids exploration of mechanisms generating fusion proteins, including chromosomal aberrations and trans-splicing events.

Methodology:

Applies text mining to extract PPI evidence from literature, validates predicted interactions via online literature searches, incorporates the ChiPPI approach, and refines predictions using a Naïve Bayes classifier trained on a 358-fusion-protein dataset.

Topics

Details

Added:
11/14/2019
Last Updated:
12/9/2020

Operations

Publications

Tagore S, Gorohovski A, Jensen LJ, Frenkel-Morgenstern M. ProtFus: A Comprehensive Method Characterizing Protein-Protein Interactions of Fusion Proteins. PLOS Computational Biology. 2019;15(8):e1007239. doi:10.1371/journal.pcbi.1007239. PMID:31437145. PMCID:PMC6705771.

PMID: 31437145
PMCID: PMC6705771
Funding: - VaTaT grant: 99990/10302 - Novo Nordisk Foundation: NNF14CC0001 - Israel Cancer Association: 204562 - Danish Science Agency: 0396010400

Links